Epigenetic regulation of PRAME gene in chronic myeloid leukemia
Issue Date: 
Román-Gómez, J., Jiménez-Velasco, A., Agirre, X., Castillejo, J. A. et al. Leukemia Research 2007; 31: 1521-1528
Tumor associated antigens (TAA) provide attractive targets for cancer-specific immunotherapy. PRAME is a TAA gene up-regulated in advanced phases of chronic myeloid leukemia (CML). To date, molecular mechanisms for the expression of PRAME have never been studied. We found that some Ph’-positive cell lines did not express PRAME. The expression of PRAMEwas restored in these cell lines by treatment with 5 -aza-2 -deoxycytidine, suggesting that the expression of PRAME is mainly suppressed by hypermethylation. Bisulfite sequencing analysis of the CpG sites of the PRAME exon 2 in these cancer cell lines revealed a close relationship between the methylation status of the PRAME gene and its expression. A methylation-specific PCR analysis demonstrated that hypomethylation of PRAME was significantly more frequent in CML blast crisis (70%) than in chronic phase (36%) (P = 0.01) and was correlated with high expression levels of PRAME transcripts (P < 0.0001). These results suggest that hypomethylation of PRAME up-regulates its expression in CML and might play a significant role in the progression of the disease.

Files in This Item:
There are no files associated with this item.

Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.